Outcomes of Kidney Transplant Recipients Minimally Immunosuppressed: A Cohort Study Analysis
1Institute for Transplantation, Urology and Nephrology (ITUN), CHU Nantes, RTRS «
Centaure », INSERM U1064, Université
de Nantes, Nantes, France
2EA 4275 SPHERE
Biostatistics, Pharmacoepidemiology and Human Sciences Research, Nantes University, Nantes, France
3Centre Hospitalier Departemental de Vendée, La Roche sur Yon, France
4Centre d'Investigation Clinique Biothérapie, Nantes, France
5Centre Hospitalier Universitaire, Nantes, France
6HLA Laboratory, Etablissement Français du Sang, Nantes, France.
Meeting: 2015 American Transplant Congress
Abstract number: D144
Keywords: Immunosuppression, Kidney transplantation, Survival
Session Information
Session Name: Poster Session D: Kidney Immunosuppression: Drug Minimization
Session Type: Poster Session
Date: Tuesday, May 5, 2015
Session Time: 5:30pm-6:30pm
Presentation Time: 5:30pm-6:30pm
Location: Exhibit Hall E
Background: Renal transplantation is the treatment of choice for endstage renal disease. Nevertheless, it involves immunosuppressive treatments with Serious Adverse Events (SAE) such as infections and cancers. In these cases, maintaining or withdrawing immunosuppression is a real dilemma. No study has been published to describe the clinical profile and the outcomes of Kidney Transplant Recipients (KTR) with a Minimally ImmunoSuppression (MIS). That may explain the high variability in the weaning decision after SAE.
Methods: We performed a retrospective study in Nantes University Hospital (France) of renal transplantations between 1982 and 2011. We included KTR weaned for calcineurin inhibitor, mammalian target of rapamycin inhibitors or CTLA4-Ig. Cumulative incidences of graft loss and death with a functional graft were analyzed using the Aalen-Johansen estimator for competing risks.
Results: In our cohort of 73 KTR, main reason for MIS was cancer (71%). The median follow-up time from the MIS was 1.8 years (range 26 days to 12.8 years). Twenty-six patients died with a functional graft and eight returned to dialysis during the follow-up. The cumulative incidences at 5 years post-MIS for death with a functional graft and for return to dialysis were estimated to be 32.5% (95% CI from 22.1% to 46.2%) and 10.2% (95% CI from 5.0% to 20.2%) respectively. KTR living with a functional graft maintained a correct renal function, and a very low rate of acute rejection episode.
Conclusion: In our cohort of KTR after minimally immunosuppression, the graft failure risk was much lower than the risk of death. Regarding the absence of clinical trial due to obvious ethical arguments, our results from routine clinical practice suggest that minimizing immunosuppressive therapy is justified for patients with related immunosuppressive SAE.
To cite this abstract in AMA style:
Querard A-H, Gillaizeau F, Couvrat-Desvergne G, Dantal J, Daguin P, Floch SLe, Castagnet S, Brouard S, Foucher Y, Giral1 M. Outcomes of Kidney Transplant Recipients Minimally Immunosuppressed: A Cohort Study Analysis [abstract]. Am J Transplant. 2015; 15 (suppl 3). https://atcmeetingabstracts.com/abstract/outcomes-of-kidney-transplant-recipients-minimally-immunosuppressed-a-cohort-study-analysis/. Accessed October 9, 2024.« Back to 2015 American Transplant Congress